Diabetic patients who used an online patient portal to refill medications increased their medication adherence and improved cholesterol levels, according to a Kaiser Permanente study published in a recent issue of Medical Care.
Formulary Watch
Latest News
All News
Advertisement
An analysis of emergency department (ED) visits over a 10-year period found that while inappropriate antibiotic use is decreasing in pediatric settings, it continues to remain a problem in adults, according to a study published ahead of print in Antimicrobial Agents and Chemotherapy.
Noninfectious diarrhea in patients with HIV on antiretroviral therapy showed improvement after treatment with 125-mg delayed-release crofelemer (Fulyzaq, Salix Pharmaceuticals) tablets, according to a study in HIV Clinical Trials.
Express Scripts and CVS Caremark are expected to expand their list of non-covered drugs for the 2015 plan year, leading to challenging pricing negotiations between branded pharmaceutical companies and PBMs.
Optimal medication adherence is important for patients who have had a heart attack in order to get maximum clinical benefit, according to a study published in the January 2014 issue of the American Heart Journal.
FDA is recommending healthcare professionals discontinue prescribing and dispensing prescription combination drug products that contain more than 325 mg of acetaminophen per tablet, capsule or other dosage unit.
All pregnant women should be screened for gestational diabetes mellitus at 24 weeks gestation, even if they have no symptoms, according to new recommendations from the U.S. Preventive Services Task Force (USPSTF).
Aetna is launching a pilot program to test the benefits of FDA-approved, prescription weight-loss drugs combined with lifestyle support.
In elderly patients with chronic lymphocytic leukemia (CLL) taking obinutuzumab (Gazyva, Genentech), also known as GA101, in combination with chlorambucil lived nearly 1 year longer without worsening of their disease compared to rituximab in combination with chlorambucil, according to a study published online ahead of print in the New England Journal of Medicine.
Hunger in the United States may have important health consequences, including a higher risk of low blood sugar, a new study suggested.
Over-the-counter sodium phosphate drugs can cause serious injury to kidneys and the heart if more than 1 dose is taken in 24 hours, according to an FDA warning.
FDA approved trametinib (Mekinist, GlaxoSmithKline) in combination with dabrafenib (Tafinlar, GlaxoSmithKline) to treat patients with advanced melanoma that is unresectable or metastatic.
Major depressive disorder (MDD) is a medical illness that is characterized by depressed mood, hopelessness, and loss of interest.1 According to the National Institute of Mental Health (NIMH), approximately 6.7% of US adult population experienced MDD, with 30.4% of these cases (2.0% of U.S. adult population) classified as severe.
FDA has approved dapagliflozin tablets (Farxiga, Bristol-Myers Squibb and AstraZeneca) to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. This marks a rebound for the drug, which FDA rejected last year, citing concerns raised by studies linking the drug to bladder cancer and liver toxicity.
A higher cumulative dose of bortezomib (Velcade, Millennium: The Takeda Oncology Company) suggested improved overall survival (OS) in previously untreated multiple myeloma patients, according to results from a retrospective subgroup analysis of the phase 3 VISTA study.
An investigational all-oral proteasome inhibitor-MLN9708 (Millennium: The Takeda Oncology Company)-plus lenalidomide and dexamethasone generated high response rates and increased depth of response with extended treatment duration in newly diagnosed multiple myeloma patients, according to data presented at the American Society of Hematology (ASH) 2013 annual meeting in New Orleans.
Evolocumab (Amgen) may offer a new treatment option for patients with dyslipidemia, according to new data from a phase 3 study.
Baxter International has initiated a voluntary recall in the United States of 2 lots of premixed sterile intravenous (IV) parenteral nutrition products: CLINIMIX (Amino Acid in Dextrose) Injection and CLINIMIX E (Amino Acid with Electrolytes in Dextrose with Calcium) Injections to the user level because of complaints of particulate matter found in the products.
In the last decade, ICU mortality due to severe pneumococcal pneumonia has significantly decreased. Improved survival is associated with earlier antibiotic prescribing and an increased use of combined antibiotic therapy, according to a study reported online in Chest.
FDA approvals, complete response, fast-track designations, priority review, first-time generic approval
Baxter International has initiated a voluntary recall in the United States of 2 lots of premixed sterile intravenous (IV) parenteral nutrition products: CLINIMIX (Amino Acid in Dextrose) Injection and CLINIMIX E (Amino Acid with Electrolytes in Dextrose with Calcium) Injections to the user level because of complaints of particulate matter found in the products.
FDA approved 27 new drugs last year, down from 39 new medications in 2012, which was a 15-year high, the Associated Press reported.
In just 1 year, with the rollout of the Affordable Care Act, the healthcare landscape has undergone its most far-reaching change in decades.
Despite some key pieces of federal legislation passed in recent years, most drugs-about 93%-are still not studied in neonates. Of those drugs that researchers have studied in this vulnerable population and that bear labels reflecting the changes in pediatric prescribing information, only about half (54%) are used in the neonatal intensive care unit (NICU).
Ongoing studies may lead FDA to stiffen its bioequivalence rules for generic antiepileptic drugs (AEDs) and others with so-called narrow therapeutic indices, according to research presented at American Epilepsy Society (AES) annual meeting recently in Washington, D.C., according to MedPage Today.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New drug class shows promise for geographic atrophy
2
Virtual care replaces, not adds, Medicare visits for health systems, analysis shows
3
CMS negotiates a 70% discount for Ozempic and Wegovy
4
Research uncovers ‘master switches’ that could portend Type 1 diabetes
5
